Search company, investor...


Founded Year



Seed VC - III | Alive

Total Raised


Last Raised

$1.99M | 3 mos ago

About Octarine

Octarine is a synthetic biology platform company enabling the development of effective cannabinoid and psychedelic therapeutics. The company's proprietary technology utilizes synthetic biology, yeast fermentation, and enzymatic derivatization to develop IP-protected drug candidates validated in pre-clinical models. The company was founded in 2018 and is based in Copenhagen, Denmark.

Headquarters Location

Howitzvej , Frederiksberg

Copenhagen, 2000,


Missing: Octarine's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Octarine's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Octarine

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Octarine is included in 5 Expert Collections, including Psychedelics.



247 items



3,834 items

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.


Early-Stage Pharma Market Map

82 items

Latest Octarine News

Corporates and their significant importance for growth

Oct 31, 2022

News Provided By Share This Article Founder of OSKARE - Alexandre OUIMET-STORRS LONDON, UNITED KINGDOM , October 31, 2022 / / -- There is an ongoing discussion in the venture capital and entrepreneurship world about the role corporations (“corporates”) can play in the development of young companies and tech ecosystems. Some people see the value corporates bring such as providing and/or accessing technical expertise and distribution channels, helping test new markets, and accelerating the development of their technology through agreements or through corporate venture/M&A. There are also detractors of corporates, who think that they bring the chains of caution, process, and bureaucracy, and might not have the best intentions in terms of having a conflict of interest and potentially deliberately slowing down the speed to market of a competitor or bringing innovation to the marketplace. Bringing in a corporate venture fund as an investor in their company can also pollute the exit for a VC. At OSKARE CAPITAL , we believe in the former but are careful to ensure that the latter is not realized when we work with corporates. Alex Ouimet-Storrs, one of Oskare’s founders, was the MD of Solvay Ventures (EMEA) and understands how corporates work. Through our experience, we understand how to avoid the pitfalls of working with corporates and ensure that our companies and corporates have a balanced relationship. We are investing in a nascent industry and new medical frontier. If you want to succeed in the long run, you need to help build an ecosystem around you with early-stage companies, sources of funding (public and private, including VC), corporates, and research institutes. Corporates play a vital role in developing applications, accessing markets, and accelerating technology developments. Given our deep understanding of how corporates work, we pride ourselves on our ability to avoid “rookie” mistakes when working with them on the fund and portfolio. The medical cannabis sector is often misunderstood to consist solely of growing and distributing cannabis. This, we are happy to say, is very far from the case. Whilst in the past the industry has been plagued with a poor reputation, we have spent a lot of time educating investors on the potential of the endocannabinoid system (a regulatory system in the human body that is activated by a state of disease, inflammation, or infection) and we are now seeing a significant uptick in typically conservative investors taking stakes in the fast-growing sector. We take a strong medical standpoint and have a good understanding of the pain points in the medical cannabis industry that need to be fixed in order to bring new plant-based medicine to a growing patient base. We are committed to those things that will build the sector’s “ecosystem”. The industry still has a lot of stigmas, and involvement now in the form of strong corporate partnerships can help solve this problem. Corporate will play a vital role in helping our portfolio companies develop and bring more of these much-needed medications to market. We recently introduced DMS’s venturing arm (DSM Ventures) to Octarine, our first investment made in 2020. Octarine is a synthetic biotech company developing novel cannabinoids (glycosides) with superior properties as well as other applications (psychedelics, sustainable dyes, and antimicrobials). DSM Ventures recently invested in Octarine’s Pre-Series A round alongside Oskare, we believe that they bring a significant amount of value through their technical knowledge and access to markets. Oskare Fund I had a first close this summer and as we continue to raise capital for our second close, we are proud to have a multinational pharmaceutical company as an investor and strategic partner. We also brought on a top 3 pharma industry CRO as a strategic partner, to help some of our portfolio companies accelerate clinical developments. Oskare Fund I is the first fund of its kind in this sector and industry. We believe in forging ties and creating win-win opportunities for our portfolio companies and selected corporate partners. This is a key component of our strategy as a fund and will certainly benefit our portfolio companies. Gaetano Insalaco

Octarine Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Octarine Rank

Octarine Frequently Asked Questions (FAQ)

  • When was Octarine founded?

    Octarine was founded in 2018.

  • Where is Octarine's headquarters?

    Octarine's headquarters is located at Howitzvej , Frederiksberg, Copenhagen.

  • What is Octarine's latest funding round?

    Octarine's latest funding round is Seed VC - III.

  • How much did Octarine raise?

    Octarine raised a total of $4.99M.

  • Who are the investors of Octarine?

    Investors of Octarine include Oskare Capital, DSM Venturing, Vækstfonden, Bruce Linton, Enexis AB and 5 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.